The Fly

Aeglea BioTherapeutics names Jeffrey Goldberg as CEO

Aeglea BioTherapeutics announced the appointment of Jeffrey Goldberg as president, CEO and member of the board of directors effective November 29. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and CEO of Immunitas Therapeutics.

Published first on TheFly

See the top stocks recommended by analysts >>

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More